Latest Insightec Stories
TIRAT CARMEL, Israel, February 19, 2013 /PRNewswire/ -- InSightec Ltd announced that it has received FDA approval to begin its pivotal Phase III clinical trial for treatment of essential tremor using ExAblate(R) Neuro. This trial is intended to provide the safety and effectiveness data about the use of ExAblate(R) Neuro in order to support FDA pre-marketing approval. ExAblate Neuro uses MR guided focused ultrasound therapy to provide an incision-less treatment, through...
TIRAT CARMEL, Israel, December 4, 2012 /PRNewswire/ -- ExAblate treatment is indicated for use for essential tremor, tremor dominant Parkinson's disease and neuropathic pain InSightec Ltd. announced that its transcranial focused ultrasound system, ExAblate Neuro, has been awarded the European CE mark for the treatment of neurological disorders in the brain including essential tremor, Parkinson's disease and neuropathic pain....
TEL AVIV, Israel, December 4, 2012 /PRNewswire/ -- Elbit Imaging Ltd. ("EI" or the "Company") (TASE, NASDAQ: EMITF) announced today that on December 3, 2012, Elbit Medical Technologies Ltd. ("Elbit Medical") (TASE: EMTC-M) (in which the Company holds approximately 90%), announced that InSightec Ltd. ("InSightec") (in which Elbit Medical holds approximately 64%, and 52.15% on a fully diluted basis) has been awarded the European CE mark for its transcranial focused ultrasound...
TEL AVIV, Israel, October 11, 2012 /PRNewswire/ -- Elbit Imaging Ltd. ("EI" or the "Company") (TASE, NASDAQ: EMITF) announced today that on October 10, 2012, Elbit Medical Technologies Ltd. ("Elbit Medical") (TASE: EMTC-M) (in which the Company holds approximately 90%), and InSightec Ltd. ("InSightec") (in which Elbit Medical holds approximately 64.3%, and 53% on a fully diluted basis), have entered into a share purchase agreement (the "Investment Agreement") with GE...
TIRAT CARMEL, Israel, August 20, 2012 /PRNewswire/ -- InSightec [http://www.insightec.com ] Ltd, the global leader in MR guided Focused Ultrasound (MRgFUS), announced that it has received approval from the US Food and Drug Administration (FDA) to begin a Phase I clinical trial evaluating the use of its ExAblate(R) Neuro [http://www.insightec.com/ExAblate-Neuro.html ] system for the treatment of patients with tremor dominant Parkinson's Disease. Thirty patients who...
TEL AVIV, Israel, February 27, 2012 /PRNewswire/ -- Elbit Imaging Ltd. (NASDAQ: EMITF) ("Elbit" "Company") announced that it's subsidiary, Elbit Medical Technologies Ltd. (TASE: ELMDT) ("EMT"), (in which the Company holds approximately 90% and approximately 93% on a fully diluted basis), announced today that InSightec Ltd. (in which the Company together with EMT holds approximately 66%) ("InSightec"), and InSightec's wholly owned subsidiary have entered into long term funding...
TIRAT CARMEL, Israel, January 24, 2012 /PRNewswire/ -- InSightec Ltd, the leader in MR guided Focused Ultrasound therapy, announced that it has submitted a premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for its ExAblate treatment of pain palliation of bone metastases. [http://www.bone-pain-palliation.co.uk ] ExAblate uses MR guided focused ultrasound (MRgFUS) to treat the pain caused by bone metastases non-invasively and without ionizing...
TIRAT CARMEL, Israel, January 3, 2012 /PRNewswire/ -- InSightec Ltd, the global leader in MR guided Focused Ultrasound (MRgFUS) therapy, announced today that it has completed enrollment in the world's first feasibility study [http://www.clinicaltrials.gov/ct2/show/NCT01304758?term=ExAblate&rank=4 ] evaluating the use of MRgFUS for treatment of Essential [http://www.insightec.com/Essential_Tremor.html ] Tremor, using ExAblate(R) Neuro at University of Virginia...
TIRAT CARMEL, Israel, November 27, 2011 /PRNewswire/ -- InSightec Ltd announced that NICE, the National Institute for Health and Clinical Excellence of the NHS in the UK, announced new favorable guidelines for the treatment of uterine fibroids using MR guided Focused Ultrasound. The new guidelines state that the current evidence on the efficacy of magnetic resonance image (MRI)-guided transcutaneous focused ultrasound treatment for uterine fibroids and evidence on safety are...
Results of first-in-world study could open doors to treating other brain disorders WASHINGTON, Oct. 3, 2011 /PRNewswire-USNewswire/ -- In a presentation at the Congress of Neurological Surgeons today, University of Virginia neurosurgeon W. Jeffrey Elias, MD reported that preliminary results of a pilot clinical trial indicate that MR-guided focused ultrasound has the potential to safely and effectively control essential tremor (ET), a common neurological condition that affects 10...
